Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 9;6:e2100242. doi: 10.1200/PO.21.00242

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

PMC Copyright notice

FIG 4. — Utilization of esophagogastric PDXs for investigation of genomically driven therapeutic strategies. (A) A PDX was generated from a patient with HER2-positive gastric cancer after progression on first-line trastuzumab and second-line afatinib. Next-generation sequencing revealed a mutation in MTOR (VUS) in clinical sequencing that was retained in the PDX. (B) Efficacy of afatinib and MTOR inhibitors in an ERBB2-amplified/MTOR-altered PDX. (C) A PDX was generated from a patient with a VUS in ERBB3 after progression on afatinib. (D) Efficacy of afatinib or a dual EGFR/HER3 inhibitor (duligotuzumab) as monotherapy or in combination. *P < .05, **P < .01, ***P < .001; Student's t-test. 5-FU, fluorouracil; Carbo, carboplatin; Cis, cisplatin; DTX, docetaxel; FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; HER2, human epidermal growth factor receptor 2; Irino, irinotecan; PDX, patient-derived xenograft; Tras, trastuzumab.